Royce & Associates LP lowered its position in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 7.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 994,300 shares of the company's stock after selling 75,260 shares during the period. Royce & Associates LP owned 5.38% of OptimizeRx worth $8,611,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its stake in shares of OptimizeRx by 2.1% in the 1st quarter. Bank of New York Mellon Corp now owns 89,538 shares of the company's stock worth $775,000 after buying an additional 1,826 shares during the last quarter. Rhumbline Advisers grew its holdings in OptimizeRx by 10.5% during the first quarter. Rhumbline Advisers now owns 27,785 shares of the company's stock valued at $241,000 after purchasing an additional 2,636 shares during the period. Wells Fargo & Company MN grew its holdings in OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after purchasing an additional 2,797 shares during the period. Barclays PLC grew its holdings in OptimizeRx by 13.5% during the fourth quarter. Barclays PLC now owns 30,574 shares of the company's stock valued at $148,000 after purchasing an additional 3,640 shares during the period. Finally, GAMMA Investing LLC bought a new stake in OptimizeRx during the first quarter valued at about $33,000. Institutional investors own 76.47% of the company's stock.
OptimizeRx Stock Performance
OPRX stock traded down $0.68 during midday trading on Tuesday, reaching $13.12. The stock had a trading volume of 38,839 shares, compared to its average volume of 370,523. The stock has a market cap of $242.72 million, a PE ratio of -15.65, a P/E/G ratio of 4.78 and a beta of 1.34. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.82 and a current ratio of 2.82. The firm has a fifty day simple moving average of $13.30 and a two-hundred day simple moving average of $9.38. OptimizeRx Corp. has a 52-week low of $3.78 and a 52-week high of $15.71.
OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.19. The company had revenue of $21.93 million for the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a negative return on equity of 0.29% and a negative net margin of 16.33%. As a group, equities research analysts anticipate that OptimizeRx Corp. will post -0.33 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on OPRX. Wall Street Zen upgraded OptimizeRx from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Stifel Nicolaus boosted their target price on OptimizeRx from $12.50 to $16.00 and gave the stock a "buy" rating in a research report on Monday, June 9th. Roth Capital reissued a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. JMP Securities boosted their price objective on OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a research note on Tuesday, May 13th. Finally, B. Riley reissued a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $10.81.
Check Out Our Latest Research Report on OptimizeRx
OptimizeRx Company Profile
(
Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Read More
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
